J&J's Cordis seeks to boost Cypher stent with DTC ads

Share this article:

With Abbott and Medtronic crowding into a market it has long split with Boston Scientific, Johnson & Johnson's Cordis is looking to raise the profile of its Cypher stent with a consumer advertising campaign – a possible first for the category.

The company launched newspaper ads earlier this month in The New York Times, The Wall Street Journal and USA Today. The ads, by BBDO, show an actual-size image of the stent under headlines reading “Tennis partner,” “Hiking gear” and “Gym Equipment.” Copy advises angina sufferers that a Cypher stent “can help get your blood pumping and your body moving once again. So you can get back to living life – playing tennis, running, working out, even sexual activity – without chest pains.”

“The goal is to help facilitate discussion between patients and physicians about coronary artery disease, the treatment options and of course, Cypher as well,” said Carol Goodrich, director of corporate communications for Cordis.

A revamped product site, featuring new patient information, went live in September, and the firm is employing search engine optimization to boost its rankings in Yahoo and WebMD searches.

On the professional side, the company fielded a massive presence at this week's Transcatheter Cardiovascular Therapeutics conference for interventional cardiologists in Washington, DC. New journal ads, by BBDO's Omnicom sibling Harrison + Star, will debut soon.

Edelman is handling PR for the effort, while interactive is being handled in-house by J&J's global advertising department.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.